Guest Post -- Obvious To Try My Patience: Federal Circuit's Evolving Measure of Obviousness under 35 U.S.C. § 103

by McDonnell Boehnen Hulbert & Berghoff LLP

[author: Jon Schuchardt*]

Nothing endures but change.    –Heraclitus
Plus ça change, plus c'est la même chose.    –Jean-Baptiste Alphonse Karr

Federal Circuit SealWhen I was your age, and Pluto was a planet, "obvious to try" was not the standard for evaluating patentability under 35 USC § 103.  In KSR v. Teleflex, the US Supreme Court qualified this by rejecting the Federal Circuit's "TSM" test in favor of a more flexible standard.  Thereafter, a skilled person might respond to a "design need" or "market pressure" to solve a problem having only a "finite number of predictable solutions."  Such an application of "common sense" would be unpatentable and "obvious to try."  Perhaps your patience has also worn thin in considering the possibilities?

Recent Federal Circuit decisions continue to shape the law of obviousness and the meaning of "obvious to try."  Here are three examples:

1.  Leo Pharmaceuticals v. Rea (Fed. Cir., August 12, 2013)

In Leo, the CAFC reversed a Board decision that held Leo's patent obvious in an inter partes reexamination challenge.  The invention related to a psoriasis treatment that combined a Vitamin D analog, a corticosteroid, and a non-aqueous solvent (polyether, fatty alcohol, or fatty ester).  The prior art taught that Vitamin D treatments required high pH (8), while corticosteroids needed low pH (4-5).  Consequently, physicians prescribed a two-drug regimen that suffered from poor patient compliance.  In evaluating the art, the Board reasoned that the skilled person would have been able to choose what ingredients to include or exclude in formulating Vitamin D analogs and steroids.

"To the contrary," wrote Chief Judge Rader, "the breadth of these choices and the numerous combinations indicate that these disclosures would not have rendered the claimed invention obvious to try."  Citing In re Cyclobenzaprine litigation: "where the prior art, at best gives only general guidance as to the particular form of the claimed invention or how to achieve it, relying on an obvious-to-try theory to support an obviousness finding is impermissible."  While the prior art had identified Vitamin D analogs and steroids as effective for treating psoriasis, "the same prior art gave no direction as to which of the many possible combination choices were likely to be successful."

2.  Sanofi-Aventis v. Glenmark (Fed. Cir., April 21, 2014)

Generic drug maker Glenmark admitted infringement at trial but argued that Sanofi-Aventis's patent (US 5,721,244) covering its Tarka® antihypertension drug (a combination of a calcium antagonist and trandalopril) was invalid under Section 103.  The structure of trandalopril includes a bicyclic octahydroindole moiety:


Prior art compositions used with calcium antagonists included otherwise structurally similar single-ring pyrrolidine analogs such as enalopril:


Glenmark urged that the district court erred as a matter of law because the combination of trandalopril and a calcium antagonist was "obvious to try."  In particular, Glenmark argued that because monocyclic inhibitors such as enalopril were known, it was obvious to try combinations of any calcium antagonist and any known ACE inhibitor, including trandalopril.

The '244 patent described the compounds and provided exemplary formulations, but it gave no performance results or any indication of advantages of the claimed compositions compared with known alternatives.  As luck would have it, the compounds were eventually found to have advantages.

At trial, expert witnesses (not surprisingly) disagreed about whether it would have mattered to the skilled person to have one ring or two to fill the pocket of the ACE enzyme to inhibit its activity.  The parties did not dispute that the claimed combination had longer-lasting effectiveness and improved kidney and blood vessel function that were not suggested by the prior art.

Nonetheless, Glenmark argued that the combination was unpatentable as a matter of law, and the patent owner's later discovery or unexpected or advantageous properties could not be relied upon to demonstrate nonobviousness.  "That is incorrect," wrote Judge Newman, "patentability may consider all of the characteristics possessed by the claimed invention, whenever those characteristics become manifest."  Citing KSR, the court reminded us that "obvious to try" requires a "finite (and small in the context of the art) number of options" that are "easily traversed."

3.  Hoffmann LaRoche v. Apotex et al. (Fed. Cir., April 11, 2014)

The CAFC affirmed (2:1) a New Jersey district court's summary judgment ruling that patents owned by Hoffmann-La Roche covering Boniva®, its once-a-month drug for treating osteoporosis, were invalid under 35 U.S.C. § 103.  Ibandronate, a bisphosphonate, was approved by the FDA in 2005.  After generic drug manufacturers submitted ANDAs to the FDA seeking approval to manufacture ibandronate prior to expiration of the patents, Roche sued for infringement.

Despite Roche's arguments that a once-monthly 150-mg dose of ibandronate provided an unexpected improvement in bioavailability of the drug compared with the usual 2.5-mg daily dose, the district court concluded that once-a-month dosing of ibandronate was established in the prior art, and that a combination of references suggested that the 150-mg monthly dose was "obvious to try."  The lower court ruled that Roche's bioavailability argument, which was raised for the first time at oral argument, "does not rise to the level of a mere scintilla, and it is not sufficient to defeat the motion for summary judgment."

The Federal Circuit agreed that a monthly 150-mg dose was obvious.  It cited trade journal articles and earlier patents that described monthly dosing of bisphosphonates, including ibandronate, as a solution for poor patient compliance with daily regimens.  The court found a 2001 article by Riis on intermittent versus daily dosages persuasive.  Riis concluded that "it is the total dose over a predefined period and not the dosing regimens that is the determining factor for effect on bone mass and architecture after ibandronate treatment."  After considering Riss and references that taught to use 5 mg per day or 35 mg per week, the court concluded that a monthly 150 mg dose was at the very least "obvious to try," and there was a reasonable expectation of success in treating osteoporosis with the once-a-month 150-mg dose.  The court also dismissed Roche's argument that the art suggested adverse gastrointestinal side effects of higher doses of bisphosphonates.  While the bioavailability argument had some appeal, the majority considered it insufficient to "rebut the strong showing that the prior art disclosed monthly dosing and that there was a reason to set the dose at 150 mg."

Judge Newman's patience was obviously "tried" because she posted a stinging dissent.  The ruling "violates the principles of Graham v. John Deere Co.  . . . (all factors must be considered) . . . violates the guidance of KSR  . . . (the standard of obvious-to-try requires a limited number of specified alternatives offering a likelihood of success in light of the prior art and common sense)" and invokes "hindsight to reconstruct the patented subject matter."  Judge Newman remarked that the FDA "refused to approve the 5 mg dose due to its toxic effects.  Surely this leads away from the obviousness of a single dose thirty times larger."  She disposed of key references and criticized the majority's reliance on the Riis study:  "Riis makes no suggestion that the once-a-month dosing at the high dosage used by Roche could replace Riis' elaborate procedure."  The evidence of long-felt need, failure of others, and commercial success provided by Roche was "unrebutted" by the challengers' experts.  "Their only argument was that it would have been "obvious to try" the Roche method.  "The extensive experimentation with other regimens and dosages demonstrates that this selection was not obvious to try."

Predictably, in the post-KSR world, district courts struggle with what it means to be "obvious to try."  However, as the cases discussed above demonstrate, even the Federal Circuit judges still disagree about what is "obvious to try" and therefore unpatentable.  Like our definition of "planet," the law of obviousness evolves, and the only thing we can be sure of (aside from death and taxes) is that change endures.

Dr. Schuchardt Partner with Dilworth IP.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDonnell Boehnen Hulbert & Berghoff LLP | Attorney Advertising

Written by:

McDonnell Boehnen Hulbert & Berghoff LLP

McDonnell Boehnen Hulbert & Berghoff LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.